Key Points
CHICAGO, Nov 9 (Reuters) - A new class of weight loss drugs is transforming the U.S. healthcare system in ways that could extend to equally hard-to-treat areas like substance abuse, according to speakers at the Reuters Events Total Health conference in Chicago this week...
The U.S. Food and Drug Administration on Wednesday said Eli Lilly (LLY.N) could begin selling its drug tirzepatide for weight loss, making it the second obesity drug in a class known as GLP-1s..
"This opens up really some dramatic new opportunities in terms of control of the satiety region of the brain, but also other regions where addiction might be controlled," said Lawrence Tabak, principal deputy director at the U.S. National Institutes of Health (NIH), during an interview at Total Health on Wednesday...
He said NIH-supported studies are still "very much a work in progress," and the drugs can cause side effects, but "it does open up a whole new set of possibilities to control things like obesity, metabolism in general, perhaps other addictive conditions."..
Drugstore chain Walgreens is seeing "enormous demand" for GLP-1s, said John Driscoll, president, U.S. healthcare at Walgreens Boots Alliance (WBA.O)...
You might be interested in
More evidence needed on Lilly's weight loss drug, UK watchdog says
27, Jun, 23UK's drug cost-effectiveness watchdog on Tuesday did not recommend Eli Lilly's weight loss drug for adults with diabetes, saying more evidence was needed before it could be used by the National Health Service (NHS).
Belgium seizes fake weight-loss drugs containing insulin
30, Oct, 23Belgium’s drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisk's (NOVOb.CO) popular obesity drug Wegovy, in which the injector pens contained insulin.
Weight-loss drugs: What and for whom are they good for?
02, Jan, 24Can weight-loss drugs treat heart and kidney diseases to conditions such as Parkinson's and alcohol addiction? What and for whom are these drugs good for? | Health
Has a 'magical' weight loss drug finally arrived? Hopes soar with US firm's never-before-seen results
29, Jun, 23Patients who got a weekly injection of the experimental anti-obesity drug retatrutide lost up to 24 per cent of their body weight in 48 weeks, show phase-2 trials published this week.
Blockbuster weight loss and anti-diabetes drugs could soon be available in India
12, Aug, 24Aditi Tandon New Delhi, August 8 The USFDA-approved blockbuster weight loss and anti-diabetes drugs—Ozempic and Wegovy—could soon make it to the Indian market. The Ministry of Health on Thursday approved local clinical trial waivers for high-end select drugs approved by...
Analysis: Europe faces long wait for weight-loss drugs as governments eye costs
10, Jul, 23Novo Nordisk (NOVOb.CO) will start selling its hugely popular obesity drug Wegovy in Germany this month, its third European market, but only people who pay from their own pocket or have certain private health insurance plans will be able to get it.
Weight loss without Wegovy’s side-effects on biotech firms' radar
07, Jul, 23Weight-loss drug Wegovy helped Rebecca Vogt achieve a major goal - shedding the weight she had not managed to drop since giving birth. But, after a particularly brutal day in the bathroom suffering from vomiting and diarrhoea, she called it quits.
Exclusive: WHO to consider adding obesity drugs to 'essential' medicines list
02, Apr, 23Drugs that combat obesity are under consideration for the first time for the World Health Organization's "essential medicines list," used to guide government purchasing decisions in low- and middle-income countries, the U.N. agency told Reuters.
Obesity drug Wegovy's popularity has US employers rethinking insurance coverage
27, Jun, 23Shawnte struggled with her weight for years before she was prescribed Novo Nordisk’s diabetes drug Ozempic for weight loss in 2020, helping the former music industry professional from New York lose more than 50 pounds over two years.